Thiogenesis Therapeutics is a clinical-stage biotech company that develops thiol-active therapeutics to treat medical diseases.
Thiogenesis Therapeutics has raised $6.6M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2026.
Thiogenesis Therapeutics is headquartered in Toronto, Canada.
Thiogenesis Therapeutics is a clinical-stage biotech company that develops thiol-active therapeutics to treat medical diseases.
Thiogenesis Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Thiogenesis Therapeutics — Funding & Investors." VCBacked, May 11, 2026, https://www.vcbacked.co/company/thiogenesis-therapeutics. Accessed September 30, 2026.
VCBacked. (2026). Thiogenesis Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/thiogenesis-therapeutics
{{cite web |title=Thiogenesis Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/thiogenesis-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated